In a recent phase Ib clinical trial, subcutaneous administration of 20 μg/kg of an ALT-803, IL-15/IL-15Rα complex fused to IgG1 Fc, in combination with nivolumab every 2 weeks in metastatic non-small-cell lung cancer patients produced an objective response of 29%, with 6 of 21 patients experiencing a partial response and 16 of 21 (76%) patients achieving disease control (53). Here, IL15RA is linked to non-small cell lung carcinoma.